Ocean Biomedical, INC

Ocean Biomedical, Inc. announced Nasdaq's final decision to delist its common stock and warrants, alongside the resignations of its CFO and a director.

Ocean Biomedical, Inc. has received a final decision from the Nasdaq Listing and Hearing Review Council affirming its delisting from The Nasdaq Stock Market.

Ocean Biomedical, Inc. announced the immediate termination of its material licenses by Elkurt, Inc. following a failure to cure contractual breaches within the stipulated 30-day period.

Ocean Biomedical, Inc. has received notice from Elkurt, Inc. terminating multiple core technology license agreements due to alleged material breaches, including over $612,000 in unpaid fees, failure to pay patent costs, and a lack of diligent product development and milestone achievement.

Ocean Biomedical faces delisting from Nasdaq and announces a strategic shift into power infrastructure and cryptocurrency investments to bolster its financial position.

Ocean Biomedical held its annual meeting of stockholders on March 28, 2025, and approved several proposals, including the election of directors and a reverse stock split.

Ocean Biomedical's Q1 2025 report reveals a net loss, a working capital deficiency, and substantial doubt about its ability to continue as a going concern, alongside a Nasdaq delisting notice.

Ocean Biomedical's Q3 2024 report reveals ongoing operating losses and a working capital deficiency, alongside efforts to secure additional funding and address debt obligations.

Ocean Biomedical's Q2 2024 report reveals ongoing financial difficulties, including a working capital deficiency and significant net losses, alongside efforts to secure additional funding and restructure debt.

Ocean Biomedical reported a net income of $13 million for Q1 2024, a significant shift from a net loss of $72.1 million in the same period last year, primarily due to gains from changes in fair value of financial instruments.

Ocean Biomedical's Q3 2023 report reveals a significant net loss and restatement of prior financials due to accounting errors related to a backstop agreement.

Ocean Biomedical has amended its Q2 2023 report to correct accounting errors related to a backstop agreement and other financial items.

Ocean Biomedical has filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, director independence, and principal accountant fees.

Ocean Biomedical, Inc. files its annual report on Form 10-K, detailing its financial results for the year ended December 31, 2024, and providing an update on its preclinical development programs.

Ocean Biomedical, a biopharmaceutical company, released its 2023 annual report, detailing its financial status and progress in developing its pipeline of therapeutic candidates.

Amy Griffith resigns from Ocean Biomedical's Board of Directors, effective at the next Annual Meeting, prompting a search for two independent directors to fill multiple vacancies.

Ocean Biomedical is asking stockholders to approve a reverse stock split, a new incentive plan, and the election of directors at its upcoming annual meeting.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly reported a 9.9% beneficial ownership stake in Ocean Biomedical, Inc. as of December 31, 2024.